NCT05325645 - Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia | Biotech Hunter

Enrollment

450

Participants

Timeline

Start Date

July 21, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

March 31, 2026

Conditions

Acute Schizophrenia

Interventions

DRUG

OPC-34712FUM/ Brexpiprazole fumarate

2 brexpiprazole QW tablets 24 mg (48 mg/dose) will be orally administered once weekly for 7weeks.(As an initial dose, one brexpiprazole QW tablet 24 mg and one placebo tablet will be orally administered (24 mg/dose))

DRUG

Placebo

Two placebo tablets will be orally administered once weekly for 7weeks.

Trial Locations (1)

Unknown

RECRUITING

Hayakawa Clinic, Kure-shi